---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-25-000049"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:20:19.203314+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexicon Q3 2025 net loss narrows to $12.8M; pipeline advances with FDA milestones on track

## Summary
- Q3 revenue $14.2M (from $1.8M YoY) driven by $13.2M Novo Nordisk licensing; net loss $12.8M vs $64.8M prior year.
- Cash and investments $145M as of Sep 30, down from $238M at Dec 31, 2024, but company says strong footing.
- End-of-Phase 2 meeting for pilavapadin (DPNP) with FDA scheduled by year-end; partnership discussions ongoing.
- LX9851 IND-enabling studies completed and handed to Novo Nordisk; near-term milestone potential $30M.
- SONATA-HCM Phase 3 enrollment on target for 2026; 130 sites initiated. Zynquista resubmission feedback expected Q4 2025.

## SEC filing metadata
- accession: 0001062822-25-000049
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000049/0001062822-25-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282225000049/lxrx-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-25-000049
- JSON: https://secwatch.observer/filing/0001062822-25-000049.json
- Plain text: https://secwatch.observer/filing/0001062822-25-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.